2 Reasons to Appreciate ZTS (and 1 Reason for Caution)

Zoetis Stock: Recent Performance and Investor Considerations

In the past half year, Zoetis shares have dropped to $129.91, reflecting a 16.4% decline. This stands in sharp contrast to the S&P 500, which has climbed 7.2% during the same period. Such underperformance may leave investors questioning their next steps.

With the stock’s recent weakness, is this a buying opportunity for ZTS?

What Makes Zoetis a Topic of Discussion?

Zoetis (NYSE:ZTS) became an independent company in 2013 after separating from Pfizer, establishing itself as the largest dedicated animal health business globally. The company specializes in the discovery, development, and sale of medicines, vaccines, diagnostic tools, and services for both companion animals and livestock worldwide.

Key Strengths of Zoetis

1. Consistent Growth in Constant Currency Revenue

For pharmaceutical companies, constant currency revenue is a valuable measure as it removes the impact of currency fluctuations, providing a clearer view of underlying business trends. Over the past two years, Zoetis has achieved an average annual growth rate of 9.1% in constant currency revenue, demonstrating its ability to expand internationally regardless of broader economic conditions.

Zoetis Constant Currency Revenue Growth

2. Exceptional Return on Invested Capital (ROIC)

While growth is important, the efficiency with which a company uses its capital is equally vital. ROIC measures how effectively a company generates operating profit from its capital base. Zoetis has maintained an impressive five-year average ROIC of 29.2%, placing it among the top performers in the healthcare sector. This highlights management’s skill in allocating resources to high-return opportunities and delivering value to shareholders.

Zoetis Trailing 12-Month Return On Invested Capital

A Cautionary Note

Slower Long-Term Revenue Expansion

Long-term sales growth is a key indicator of a company’s overall quality. While short-term gains are possible for many businesses, sustained growth over several years is a sign of true strength. Unfortunately, Zoetis’s revenue has grown at a compounded annual rate of just 7.2% over the past five years, which is modest compared to other healthcare firms. Despite this, Zoetis still offers several attractive qualities.

Zoetis Quarterly Revenue

Conclusion: Is Zoetis Worth Considering?

Zoetis presents significant growth potential, though some concerns remain. Following its recent decline, the stock is trading at a forward P/E of 18.4 (or $129.91 per share). Should investors consider buying now?

Building a Resilient Portfolio with Quality Stocks

Relying on just a handful of stocks can leave your investments vulnerable. Now is a limited window to secure high-quality assets before market conditions shift and prices rise.

Don’t wait for the next bout of market volatility. Discover our Top 5 Strong Momentum Stocks for this week. This carefully selected list features high-quality stocks that have delivered a remarkable 244% return over the past five years (as of June 30, 2025).

Our selections include well-known leaders like Nvidia, which soared 1,326% from June 2020 to June 2025, as well as lesser-known companies such as Comfort Systems, which achieved a 782% five-year return. Start your search for the next standout performer with StockStory today.